Found: 16
Select item for more details and to access through your institution.
Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
- Published in:
- Pharmacology Research & Perspectives, 2019, v. 7, n. 2, p. 1, doi. 10.1002/prp2.470
- By:
- Publication type:
- Article
Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer's disease: A phase 2, double‐blind, randomized, placebo‐controlled trial: Human/Human trials: Anti‐amyloid.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.044628
- By:
- Publication type:
- Article
Impact of Isolation During the COVID-19 Pandemic on the Patient Burden of Parkinson's Disease: A PMD Alliance Survey.
- Published in:
- Neuropsychiatric Disease & Treatment, 2022, v. 18, p. 633, doi. 10.2147/NDT.S351691
- By:
- Publication type:
- Article
QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.
- Published in:
- Neuropsychiatric Disease & Treatment, 2021, v. 17, p. 3791, doi. 10.2147/NDT.S324145
- By:
- Publication type:
- Article
Movement Disorder Specialists Survey Regarding Use of Telemedicine During the COVID-19 Pandemic.
- Published in:
- Telemedicine & e-Health, 2022, v. 28, n. 11, p. 1651, doi. 10.1089/tmj.2021.0474
- By:
- Publication type:
- Article
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.
- Published in:
- CNS Drugs, 2024, v. 38, n. 5, p. 333, doi. 10.1007/s40263-024-01084-1
- By:
- Publication type:
- Article
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.
- Published in:
- JAMA Neurology, 2020, v. 77, n. 3, p. 309, doi. 10.1001/jamaneurol.2019.4200
- By:
- Publication type:
- Article
Sialorrhea in Parkinson's Disease.
- Published in:
- Toxins, 2020, v. 12, n. 11, p. 691, doi. 10.3390/toxins12110691
- By:
- Publication type:
- Article
Erratum to: Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases.
- Published in:
- Human Molecular Genetics, 2021, v. 30, n. 13, p. 1271, doi. 10.1093/hmg/ddab082
- By:
- Publication type:
- Article
Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases.
- Published in:
- Human Molecular Genetics, 2020, v. 29, n. 17, p. 2882, doi. 10.1093/hmg/ddaa177
- By:
- Publication type:
- Article
Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
- Published in:
- Movement Disorders, 2021, v. 36, n. 3, p. 740, doi. 10.1002/mds.28389
- By:
- Publication type:
- Article
Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022, v. 8, n. 1, p. 1, doi. 10.1002/trc2.12296
- By:
- Publication type:
- Article
Correction to: Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel.
- Published in:
- Neurology & Therapy, 2022, v. 11, n. 4, p. 1571, doi. 10.1007/s40120-022-00388-y
- By:
- Publication type:
- Article
Cardiac Cephalgia.
- Published in:
- Current Pain & Headache Reports, 2015, v. 19, n. 4, p. 1, doi. 10.1007/s11916-015-0481-4
- By:
- Publication type:
- Article